Hepatitis B infection has a complex natural history and causes a wide spectrum of disease. Although effective vaccines are available, universal vaccination has yet not been reached. Currently, an estimated 350 million people are chronically infected, and 0.5-1.2 million subjects die every year due to long-term sequalae of hepatitis B related chronic liver disease, such as liver cirrhosis and hepatocellular carcinoma Despite evidence-based treatment guidelines areas of disagreement on the management of chronic hepatitis B virus (HBV) infection still exist. With the currently approved treatment options the ultimate goal is to prevent the development of long-term sequelae of chronic liver disease. Current treatment strategies consist of either therapies with fi nite duration that aims to achieve sustained off-treatment remission (interferon-based therapy), or long-term therapy that aims to maintain on-treatment response (nucleos(t)ide analogues).

Additional Metadata
Keywords HIV, Hepatitis B, infectious diseases, liver diseases, virology
Promotor H.L.A. Janssen (Harry)
Publisher Erasmus University Rotterdam
Sponsor Erasmus MC Rotterdam, Nederlandse Vereniging voor Gastroenterologie, Novartis, Gilead Sciences, Bristol-Myers Squibb, J.E. Jurriaanse Stichting
ISBN 978-90-8559-095-8
Persistent URL hdl.handle.net/1765/21420
Citation
Reijnders, J.G.P. (2010, November 24). Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/21420